Last reviewed · How we verify
NCT03125278
Patient Knowledge of Medication Indication
trial testing Medication knowledge in Medical Audit in 40 participants. Completed in 31 October 2017.
2 May 2017
Quick facts
| Lead sponsor | HealthPartners Institute |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 11 April 2017 |
| Primary completion | 2 May 2017 |
| Estimated completion | 31 October 2017 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Medication knowledge
Conditions studied
- Medical Audit — all drugs for Medical Audit →
Sponsor
HealthPartners Institute
Who can join
18 and older, any sex, with Medical Audit. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a study to compare patient knowledge about the indications of their medications between two sites. Regions Hospital has a population of patients that receive the medication indication on the label for any new or changed medications at the time of patient discharge. Brigham Women's Health follows a standard policy of discharge medication labels including the name of the medication and instructions for use without any indication of what the medication is intended to treat. Consented patient will receive a phone call where researchers will ask about which medications they are taking and other questions about those medications. The study population will be patients recently discharged from the hospital with 1 or more new or changed medications
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03125278
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other HealthPartners Institute trials
Trials by the same sponsor.
- NCT07127133 — An Insole and Ankle Device for Monitoring Cognitive Decline in Individuals at Risk for Alzheimer's Disease and/or Alzhei · NA · not yet recruiting
- NCT07354919 — Axelopran in Advanced Cancers · Phase 2 · not yet recruiting
- NCT06434038 — Measurement of Insulin Levels in the Cerebrospinal Fluid of Healthy Adults After a Single Intranasal Dose - Middle Age · Phase 1 · withdrawn
- NCT06914726 — Patient Centered Clinical Decision Support for Hereditary Cancer Syndromes · NA · enrolling by invitation
- NCT06999330 — TMS in Anxiety-Parkinson's Disease · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03125278 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by HealthPartners Institute
- Last refreshed: 7 June 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03125278.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing